Hemostatic spray powder TC-325 for GI bleeding in a nationwide study: survival and predictors of failure via competing risks analysis

Autor: Rodríguez de Santiago E, Burgos-Santamaria D, Pérez-Carazo L, Brullet E, Ciriano L, Pons FR, Ángel de Jorge Turrión M, Prados S, Pérez-Corte D, Becerro-Gonzalez I, Martinez-Moneo E, Barturen A, Fernández-Urién I, López-Serrano A, Ferre-Aracil C, Lopez-Ibañez M, Carbonell C, Nogales O, Martínez-Bauer E, Lantarón ÁT, Pagano G, Vázquez-Sequeiros E, Albillos A, TC-325 collaboration project. Endoscopy group of the Spanish Association of Gast, García AG, Volpato N, Rodriguez-Escaja C, García-Alonso FJ, Sevilla-Ribota S, Marcos Prieto HM, Chavarría-Herbozo CM, Murcia O, Aranda-Hernández J, Borobia R, Lledó JG, Santander C, Coto D, Oyón D, Polo IO, González-Haba Ruíz M, Torres CF, De Benito Sanz M, Peñas B, Parejo S, Juzgado D, Ibañez A

Publikováno v: Gastrointestinal endoscopy
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)

Background and Aims: TC-325 (Hemospray, Cook Medical, Winston-Salem, NC) is an inorganic hemostatic powder recently approved by the U.S. Food and Drug Administration. This study aimed to examine the effectiveness, safety, and predictors of TC-325 fai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::1004c0a81330610399960c0b0fee9c15
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=3697

FRI-095 - Previous and resolved hepatitis B virus infection is not a risk factor for the development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus or alcohol

Autor: de Jorge, M.A., González-Diéguez, M.L., Alvarez-Navascues, C., Castaño, A., Varela, M., Cadahia, V., Rodríguez-Escaja, C., Rubio, E., Rodriguez, M.

Publikováno v: In Journal of Hepatology 2017 66(1) Supplement:S455-S455

THU-148 - Transient elastography evolution in non treated patients with chronic hepatitis B (CHB) infection

Autor: González-Diéguez, M.L., de Jorge, M.A., Alvarez-Navascues, C., Rodríguez-Escaja, C., Rubio, E., Castaño, A., Cadahia, V., Varela, M., Rodriguez, M.

Publikováno v: In Journal of Hepatology 2017 66(1) Supplement:S254-S254

THU-077 - Prospective validation of a score to predict hepatocellular carcinoma in patients with hepatitis C cirrhosis that takes into account sustained virological response. Influence of direct-acting antivirals

Autor: Castaño, A., Alvarez-Navascues, C., Rodriguez-Escaja, C., de Jorge, M.A., Rubio, E., Gonzalez-Dieguez, L., Varela, M., Cadahia, V., Manuel, R.

Publikováno v: In Journal of Hepatology 2017 66(1) Supplement:S209-S209

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.